undamentalytics Newsletter
Sign in

Kyverna Therapeutics, Inc. (KYTX) stock

Add to watchlist

Add holding +

NASDAQ: KYTX Nasdaq Biotechnology Next results ~November 11, 2026

Kyverna Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 1 selling2 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds67 adding, 49 cuttingOf 31 active managers that changed their stake, 12 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Kyverna Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 88% and a beta of 2.1 against the S&P 500.
  • Heavily shorted. 18.1% of the shares available to trade are sold short (9.4 days of average volume to cover).

Latest results

Earnings per share
-$0.63 against an average estimate of -$0.68: beat by 7.3%
Share reaction
+2.0% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 11, 2026; average EPS estimate -$0.69

Kyverna Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-7.9%
  • 1 week-0.9%
  • 1 month-16.1%
  • This year-44.5%
  • 1 year-25.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Results
  3. Agreement
  4. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Kyverna Therapeutics, Inc. valuation models and calculator

No model value for Kyverna Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.69 (range −$0.77 to −$0.65) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.77 +24% — 0%
Next −$3.17 −14% $17m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −3.7% on 90 days ago. In the last 30 days, 3 analysts raised Kyverna Therapeutics, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Kyverna Therapeutics, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.88 Current fiscal year, 60 days ago: −$2.77 Current fiscal year, 30 days ago: −$2.77 Current fiscal year, 7 days ago: −$2.77 Current fiscal year, Now: −$2.77 −$2.77 Next fiscal year, 90 days ago: −$2.95 Next fiscal year, 60 days ago: −$3.07 Next fiscal year, 30 days ago: −$3.17 Next fiscal year, 7 days ago: −$3.17 Next fiscal year, Now: −$3.17 −$3.17

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.88−$2.95
60 days ago −$2.77−$3.07
30 days ago −$2.77−$3.17
7 days ago −$2.77−$3.17
Now −$2.77−$3.17

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.68 −$0.63 +7.3%
Dec 2025 −$0.86 −$0.80 +6.8%
Sept 2025 −$0.95 −$0.85 +10.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026
Buy6100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026246
  2. Sep 2026246
  3. Aug 2026246
  4. Jul 2026246

Counts of recommendations published by analysts covering Kyverna Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
18.1%
of tradable shares
Days to cover
9.45
at average volume
Short interest, 1 month
+9%
to October 15, 2026
Held by institutions
81%
of shares
Held by insiders
7.0%
of shares
Employees
149
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
KYTX+151%−45%
Industry peers (median)−5%−26%
S&P 500+18%+11%
Months that ended higher
KYTX75%46%
S&P 50075%46%
Largest fall from a high during the year
KYTX−55%−54%
S&P 500−19%−9%

Worst fall since February 9, 2024: 94% from February 9, 2024 to April 16, 2025. Getting back needed a 1545% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.22 – $11.25
From 52-week high
−53.6%
vs 50-day average
−23.7%
vs 200-day average
−35.3%
Volatility (1 year)
88%
Beta vs S&P 500
2.14

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
7 up, 5 down
typical move ±6.7%
After a week
7 up, 5 down
typical move ±11.5%
After a month
5 up, 7 down
typical move ±20.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 +2.0% −0.1% +7.7% −6.8%
May 12, 2026 +4.3% +0.4% −15.9% −23.9%
March 26, 2026 −0.9% −3.5% +12.7% +14.2%
January 12, 2026 +4.1% 0.0% +8.4% −9.3%
November 12, 2025 −7.4% −1.6% +17.6% +25.4%
August 12, 2025 +11.9% +1.4% +6.5% +33.9%
May 13, 2025 −2.7% +0.8% +8.1% +56.6%
March 27, 2025 −20.0% −2.3% −21.2% −18.0%
November 13, 2024 −8.0% −0.6% −21.1% −15.3%
August 12, 2024 +6.7% +1.7% +6.4% +6.6%
May 14, 2024 +8.5% +1.7% −6.4% −1.3%
March 26, 2024 +3.7% +0.7% −5.7% −31.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$335M
Institutions reporting
120
Shares held vs prior quarter
▲ 8.0%
Positions opened / closed
31 / 21

Top buyers and sellers, Q2 2026: 67 institutions bought and 49 sold ; the biggest buyer was Blackrock, Inc (+2.3M shares) and the biggest seller Balyasny Asset Management L.P (−1.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Gordonmd Global Investments LP $37.8M 4.2M 11.3% 0.0%
Gilead Sciences, Inc. $36.8M 4.1M 11.0% 0.0%
Blackrock, Inc. $27.9M 3.1M 8.3% ▲ 257.4%
Bain Capital Life Sciences Investors, LLC $25.7M 2.9M 7.7% ▼ 7.2%
Aigh Capital Management LLC $24.9M 2.8M 7.4% ▲ 39.8%
Deerfield Management Company, L.P. $17.8M 2.0M 5.3% 0.0%
Vanguard Capital Management LLC $16.9M 1.9M 5.0% ▲ 6.4%
Price T Rowe Associates Inc $10.6M 1.2M 3.2% ▼ 23.7%
Geode Capital Management, LLC $9.4M 1.0M 2.8% ▲ 147.6%
Insight Holdings Group, LLC $8.8M 989K 2.6% 0.0%
Morgan Stanley $8.8M 982K 2.6% ▲ 0.5%
State Street Corp $8.8M 982K 2.6% ▲ 610.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kyverna Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $2M 2 trades by 2 insiders, last 12 months Insider sales History → $292,776 1 trade by 1 insider · 100% under pre-set plans
Net ▲ $1.7M net buying
Insider Date Trade Shares Price Value
Westlake Biopartners Opportunity Fund I, L.P. 10% owner December 18, 2025 Buy 133,333 $7.50 $999,998
Seidenberg Beth C Director December 18, 2025 Buy 133,333 $7.50 $999,998
Walker Karen Marie Chief Technology Officer December 15, 2025 Sell pre-set plan 23,998 $12.20 $292,776

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 12, 2026
  • March 26, 2026
  • January 12, 2026
  • November 12, 2025
  • August 12, 2025

Recent SEC filings

Data status

When each part of this page on Kyverna Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Kyverna Therapeutics, Inc. in brief

What does Kyverna Therapeutics, Inc. do?
Kyverna Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Kyverna Therapeutics, Inc.'s stock ticker?
Kyverna Therapeutics, Inc. trades under the ticker KYTX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Kyverna Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Gordonmd Global Investments LP, Gilead Sciences, Inc. and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Kyverna Therapeutics, Inc. stock?
Over the last 12 months, Kyverna Therapeutics, Inc.'s directors and officers reported 2 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Kyverna Therapeutics, Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Kyverna Therapeutics, Inc. announces its own schedule.